: Vivos Therapeutics’ stock soars as sleep apnea device gets regulatory clearance

Vivos Therapeutics jumped more than 270% after the FDA cleared the company’s devices for severe sleep apnea.

Previous post : CFPB’s Chopra taking aim at $130 billion in credit card interest, fees Americans paid last year
Next post Washington Watch: Shein’s IPO faces frosty reception in Washington